Abstracts Archive - Page 1845 of 2425 - ACR Meeting Abstracts

Abstract Number: 2343 • 2015 ACR/ARHP Annual Meeting
Impact of Colchicine Use on the Development of Incident Coronary Artery Disease
Susanna Jeurling¹, Daria Crittenden², Mark C. Fisher³, Binita Shah⁴, Steven P. Sedlis⁴, Craig T. Tenner⁵, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Rheumatology, NYU-HJD, New York, NY, ³Rheumatology, New York Univ-HJD, New York, NY, ⁴NYU School of Medicine, Division of Cardiology, New York, NY, ⁵Medicine, NYU School of Medicine, New York, NY, ⁶NYU School of Medicine, Division of Rheumatology, New York, NY, ⁷Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with gout experience both inflammation and increased risk of cardiovascular disease (CVD). Studies suggest that colchicine reduces myocardial infarction (MI) risk, but whether…
Abstract Number: 2344 • 2015 ACR/ARHP Annual Meeting
A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine
Naomi Schlesinger¹, Thomas Bardin^2,3, Mark Bloch⁴, Karine Lheritier⁵, Uwe Machein⁵, Guido Junge⁵, Alexander So⁶ and Rieke Alten⁷, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Hopital Lariboisière, Paris, France, ³Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁷Charité Univ Medicine, Berlin, Germany
Background/Purpose: Although anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs and colchicine are the recommended treatment options for pain and inflammation management in patients (pts) with…
Abstract Number: 2345 • 2015 ACR/ARHP Annual Meeting
Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study
Prashanth Sunkureddi¹, Rüdiger Moericke², Edith Tóth³, Jacques P Brown⁴, Uwe Machein⁵, Karine Lheritier⁵, Guido Junge⁵ and Alan J Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ³Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ⁴Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients with gouty arthritis (GA) experience frequent flares with pain and inflammation. The limited available treatment options and typical comorbidities warrant effective alternative treatments1.…
Abstract Number: 2346 • 2015 ACR/ARHP Annual Meeting
Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1b Production through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells
Jung-Yoon Choe¹, Minyoung Her² and Seong-Kyu Kim³, ¹Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ²Busan Paik Hospital, Inje University, Busan, South Korea, ³Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea
Background/Purpose: This study investigated the effect of rebamipide on activation of NLRP3 inflammasome and reactive oxygen species (ROS) in monosodium urate (MSU) crystal-induced interleukin-1b (IL-1b)…
Abstract Number: 2347 • 2015 ACR/ARHP Annual Meeting
Can We Predict the Dose of Allopurinol to Achieve Target Urate?
Dan Wright¹, Stephen Duffull¹, Tony R. Merriman², Nicola Dalbeth³, Murray Barclay⁴ and Lisa K. Stamp⁴, ¹School of Pharmacy, University of Otago, Dunedin, New Zealand, ²Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Medicine, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Allopurinol is a first line urate lowering therapy in the management of gout. The observation that allopurinol hypersensitivity was associated with allopurinol dose, renal…
Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting
The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
Background/Purpose: Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
Abstract Number: 2350 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study
Pierre-Antoine Juge¹, Marie-Elise Truchetet², Sébastien Ottaviani³, Cécile Vigneau⁴, Clotilde Loustau⁵, Divi Cornec⁶, Tristan Pascart⁷, Emilie Cornec-Legall⁸, Marine Florien⁹, Florian Bailly¹⁰, Thierry Schaeverbeke⁵, Alain Saraux¹¹, Philippe Dieude¹², Rene-Marc Flipo¹³, Georges Jean-Baptiste¹⁴, Pascal Richette¹⁵, Frederic Lioté¹⁶, Thomas Bardin^17,18, Gerard H. Chales¹⁹ and Hang-Korng Ea²⁰, ¹Rheumatology Department, Centre de Viggo Petersen, Lariboisère Hospital, Paris, France, ²Rheumatology, Pellegrin Hospital, Bordeaux, France, ³Hopital Lariboisière, Paris, France, ⁴Nephrology, Rennes University Hospital, Rennes, France, ⁵Rheumatology Department, Bordeaux Hospital, Bordeaux, France, ⁶Department of rheumatology, Brest Occidentale University, Brest, France, ⁷Rheumatology, Saint-Philibert Hospital, Lille, France, ⁸Nephrology Departement, Brest Hospital, Brest, France, ⁹Rheumatology Department, Pierre-Zobda-Quitman La Meynard, Fort-de-France, France, ¹⁰Rheumatology Department, La Pitié-Salpétrière Hospital, Paris, France, ¹¹Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹²Rheumatology, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ¹³Rheumatology, University Hospital, Lille, France, ¹⁴Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort-de-France, Martinique, ¹⁵Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, ¹⁶Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹⁷Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ¹⁸Rhumatology Departement, Hôpital Lariboisière, Paris, France, ¹⁹CHU RENNES, Rennes, France, ²⁰INSERM UMR1132, Paris Diderot University, Paris, France
Background/Purpose: Although allopurinol is the first urate lowering therapy (ULT), its limited dosage in gouty patients with stage 4 or 5 chronic kidney disease (CKD…
Abstract Number: 2351 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra Steinberg, Yun-Jung Choi, Robert Martin, Charles McWherter and Pol Boudes, Cymabay Therapeutics, Newark, CA
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) for the treatment of gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular…
Abstract Number: 2352 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: In the randomized, double-blind, placebo-controlled, Phase III CRYSTAL trial, more patients taking lesinurad 200 mg (LESU200) or 400 mg (LESU400), in combination with febuxostat…
Abstract Number: 2353 • 2015 ACR/ARHP Annual Meeting
Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: A randomized, double-blind, placebo-controlled, Phase III clinical trial showed that lesinurad, a selective uric acid reabsorption inhibitor (SURI), in combination with febuxostat 80 mg…
Abstract Number: 2354 • 2015 ACR/ARHP Annual Meeting
The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Robert Terkeltaub¹, Fernando Perez-Ruiz^2,3,4, Jeff Kopicko⁵, Maple Fung⁵, Scott Adler⁶, Chris Storgard⁷, Scott Baumgartner⁵ and Nicola Dalbeth⁸, ¹Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ²Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, ³BioCruces Health Research Institute, Baracaldo, Spain, ⁴Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Previous studies have shown that long-term urate-lowering therapy (ULT) is required for improvements in gout flare frequency and tophi reduction, and that lower serum…
Abstract Number: 2355 • 2015 ACR/ARHP Annual Meeting
Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Serum Uric Acid Levels: A Randomized Controlled Trial
Na Lu¹, Yuqing Zhang², Sharan K. Rai³, Gary C. Curhan⁴ and Hyon K. Choi⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²BUSM, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Renal Division, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% of cases in the US), underscoring…
Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
JoAnne Foody¹, Robin Turpin², Beni Tidwell³ and Kathy Schulman⁴, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ³ORS, Shrewsbury, MA, ⁴Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
Abstract Number: 2357 • 2015 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors for the Prevention of Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Markus Bredemeier¹, Matheus Augusto Eisenreich¹, Lediane Moreira Lopes¹, André Luis Bittencourt Morsch², Fernando da Silva Stein², Rui d'Avila² and Guilherme Gomes Dias Campos¹, ¹Rheumatology, Hospital Nossa Senhora da Conceição - Grupo Hospital Conceição, Porto Alegre, Brazil, ²Internal Medicine, Hospital Nossa Senhora da Conceição - Grupo Hospital Conceição, Porto Alegre, Brazil
Background/Purpose: There is evidence suggesting that high levels of uric acid represent an independent cardiovascular risk factor and that the use of xanthine oxidase inhibitors…
Abstract Number: 2359 • 2015 ACR/ARHP Annual Meeting
Atorvastatin-Induced Autoimmune Myopathy: An Emerging Dominant Entity in Patients with Autoimmune Myopathy Presenting with a Pure Polymyositis Phenotype
Océane Landon-Cardinal¹, Yves Troyanov², Marvin J. Fritzler³, José Ferreira¹, Ira Targoff⁴, Eric Rich², Michelle Goulet¹, Jean-Richard Goulet¹, Josiane Bourré-Tessier², Yves Robitaille¹, Alexandra Albert⁵ and Jean-Luc Senécal², ¹Université de Montréal, Montréal, QC, Canada, ²Université de Montréal, Montreal, QC, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴University of Oklahoma, Oklahoma City, OK, ⁵Université Laval, Québec, QC, Canada
Background/Purpose: The classification of autoimmune myopathies (AIM) is evolving. Pure dermatomyositis (DM) and overlap myositis are dominant AIM subsets, while pure polymyositis (pPM) is uncommon…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].